跳至主要内容
临床试验/ACTRN12622001047785
ACTRN12622001047785
招募中
未知

Feasibility and role for comprehensive molecular evaluation for Advanced Biliary Cancer (ABC) in Australia.

Australasian Gastro-Intestinal Cancer Trials Group (AGITG)0 个研究点目标入组 50 人2022年7月28日

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
未指定
发起方
Australasian Gastro-Intestinal Cancer Trials Group (AGITG)
入组人数
50
状态
招募中
最后更新
3年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2022年7月28日
结束日期
待定
最后更新
3年前
研究类型
Interventional
性别
All

研究者

发起方
Australasian Gastro-Intestinal Cancer Trials Group (AGITG)

入排标准

入选标准

  • 1\.Males or females with suspected advanced biliary tract cancer as determined by MDT review that is either:
  • a.Locally advanced
  • b.Metastatic
  • c.Recurrent
  • 2\.Study participants either:
  • a.Are scheduled for an endoscopic procedure for the purposes of tissue diagnosis or biliary stenting
  • b.Have previously consented to biobanking of endoscopic biopsy material
  • 3\.Study participants must be 18 years of age or older at time of screening
  • 4\.ECOG Performance Status 0\-2
  • 5\.Suitability for chemotherapy

排除标准

  • 1\.Patients considered to have operable or potentially operable biliary cancer (BC)
  • 2\.Patients with hepatocellular cancer or liver metastatic disease in which the primary malignancy is not BC.
  • 3\.Evidence of systemic disease (cardiovascular, respiratory, renal, hepatic, etc.) that would preclude chemotherapy.
  • 4\.Serious medical or psychiatric conditions that might compromise protocol\-based management as judged by investigator

结局指标

主要结局

未指定

相似试验